GET HELP NOW

Monday, August 28, 2017

Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental

http://ift.tt/eA8V8J Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

from Latest Science News -- ScienceDaily http://ift.tt/2wWOKfT
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...